A股異動 | 分拆新材料業務上科創板 紫江企業連續四日漲停
格隆匯2月26日丨紫江企業(600210.SH)連續四日漲停,現報5.49元,暫成交7億元,最新總市值83億元,封單逾14萬手。公司曾於20日發公告稱,擬將控股子公司紫江新材料分拆至上交所科創板上市,分拆完成後,紫江企業仍將維持對紫江新材料的控制權。紫江新材料主營業務為鋰離子電池薄膜等新能源電池功能性材料的研發、製造和銷售,屬於新材料領域,與公司傳統包裝業務及其他業務板塊之間保持高度的業務獨立性。此外據悉,由於此前分拆子公司至科創板上市的中國鐵建、上海電氣均為國資控股,而紫江企業為民企上市公司,該方案因此成為民企上市公司拆分至科創板上市首單。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.